


## Urolithin D

<b>Cat. No.:</b>	HY-133178
<b>CAS No.:</b>	131086-98-1
<b>Molecular Formula:</b>	C <sub>13</sub> H <sub>8</sub> O <sub>6</sub>
<b>Molecular Weight:</b>	260.2
<b>Target:</b>	Ephrin Receptor
<b>Pathway:</b>	Protein Tyrosine Kinase/RTK
<b>Storage:</b>	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 125 mg/mL (480.40 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	<b>Preparing Stock Solutions</b>		1 mg	5 mg	10 mg
		1 mM	3.8432 mL	19.2160 mL	38.4320 mL
		5 mM	0.7686 mL	3.8432 mL	7.6864 mL
	10 mM	0.3843 mL	1.9216 mL	3.8432 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (7.99 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (7.99 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (7.99 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	Urolithin D is competitive and reversible antagonist of EphA receptors. Urolithin D exhibits intra-classes selectivity <sup>[1]</sup> .
--------------------	---

### REFERENCES

[1]. Giorgio C, et al. The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells. Mol Nutr Food Res. 2015 Nov;59(11):2155-67.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA